Aptadir raises €40M seed to switch silenced genes back on

Aptadir Therapeutics, a Milan biotech founded in 2024, has raised a €40M ($45M) seed round led by London’s 4BIO Capital to advance CAP1-FMR1, an RNA medicine designed to switch the silenced gene behind Fragile X syndrome back on.

European biotech has a familiar complaint: we publish the science, and someone else builds the company. This week the counterexample lands in Milan, with a seed round the size of most European biotech Series As. Below, I lay out the round, the science, and why the number matters less than where it was signed.

A London lead, an Italian bench

Aptadir announced the €40M seed on 29 September 2026. 4BIO Capital, the London firm that invests exclusively in advanced therapies, led the round. Behind it stands close to the full Italian institutional bench: returning pre-seed backer EXTEND, CDP Venture Capital, Indaco Venture Partners, XGEN Venture, Angelini Ventures, plus CE-Ventures, Kerna Ventures and the angel networks Italian Angels for Biotech and Club degli Investitori.

The company says the money will advance its “pipeline of disease-modifying investigational RNA therapeutics, including its lead candidate, CAP1-FMR1 for Fragile X Syndrome”. For scale: the round is 28 times the $1.6M pre-seed Aptadir raised at launch in September 2024, two years ago almost to the day.

“Finding truly innovative new science with such potential is a rare event,” said 4BIO managing partner Dima Kuzmin in the announcement. “We are delighted to back this novel modality.”

One enzyme, a family of switched-off genes

Aptadir builds DNMT-interacting RNAs, or DiRs: RNA molecules that block DNMT1, the enzyme that maintains the chemical marks keeping a gene switched off. Classic demethylating drugs strip those marks across the whole genome, side effects included. DiRs are designed to act on a single gene, the company says, reactivating it without touching its neighbours.

The lead application is Fragile X syndrome, which the announcement describes as the most common inherited cause of intellectual disability. In Fragile X, the FMR1 gene is silenced and the brain loses FMRP, a protein essential to its development. CAP1-FMR1 restored gene expression and function in patient-derived disease models, per the company. An earlier programme, Ce-49, targets myelodysplastic syndrome, and the platform’s roots run through founder and CEO Giovanni Amabile’s research career at Harvard Medical School and the Cancer Science Institute of Singapore.

“The magnitude of this seed round reflects the exciting potential of our DiRs technology and the quality of a truly international scientific team,” Amabile said.

An $18bn market next door to a $47M one

Why would anyone fund a drug for a $47M market? The numbers only make sense side by side. RNA therapeutics as a whole are an $18.44bn global market in 2026, forecast to reach $40.98bn by 2036, an 8.3% CAGR (Research and Markets, September 2026). The Fragile X treatment market, by contrast, was worth just $46.8M in 2025 across the US, the EU4, the UK and Japan, growing at 3.97% to 2036 (IMARC, July 2026) – tiny because every product on it treats symptoms, not the cause, for roughly 122,000 diagnosed patients across those markets in 2023 (DelveInsight, February 2025).

A disease-modifying drug would not compete for that $47M; it would make the category obsolete and price itself like a rare-disease therapy instead. That asymmetry – a small symptomatic market hiding a large curative one – is what a specialist fund underwrites.

It also puts the cheque in perspective. The European biotech rounds in our fundraising data this month include Kasvu Therapeutics’ €30M Series A for a depression drug and Prevision Medicine’s $5.4M seed for functional cancer testing. Aptadir’s seed outweighs both.

What a €40M seed in Milan changes

The hard truth is that Italy has long produced world-class biology and exported the companies built on it; the invoice usually arrives from Boston. The good news is that this syndicate looks like a system correcting itself. EXTEND – the translational vehicle CDP Venture Capital runs with Angelini Ventures and Evotec – was built precisely to carry Italian lab discoveries to fundable companies, and here it took one from a $1.6M pre-seed to a €40M seed in two years, then handed the lead to an international specialist without losing the Italian cap table.

What we are watching now: CAP1-FMR1’s path into the clinic, and whether the Series A that follows gets priced in Milan or, as usual for us, in London or Boston. Fragile X families have waited decades for a medicine aimed at the cause rather than the edges. Watch this one.